Catalyst Financial Partners LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Catalyst Financial Partners LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 25.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,757 shares of the biopharmaceutical company’s stock after selling 4,413 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Pfizer were worth $367,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Briaud Financial Planning Inc acquired a new stake in shares of Pfizer in the third quarter valued at about $30,000. GoalVest Advisory LLC boosted its stake in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new position in Pfizer in the 4th quarter valued at approximately $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 1.8 %

Shares of NYSE:PFE traded up $0.50 during midday trading on Wednesday, reaching $28.28. The company’s stock had a trading volume of 39,037,887 shares, compared to its average volume of 43,541,762. The business has a 50 day moving average price of $26.92 and a 200 day moving average price of $28.12. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The firm has a market cap of $160.11 billion, a price-to-earnings ratio of -471.17, a price-to-earnings-growth ratio of 1.17 and a beta of 0.63. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the business earned $1.23 EPS. The firm’s revenue was down 19.5% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.94%. Pfizer’s payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

A number of analysts have commented on PFE shares. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $36.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.